220 related articles for article (PubMed ID: 12793596)
1. PPAR agonists in the treatment of insulin resistance and associated arterial disease.
Camejo G
Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596
[TBL] [Abstract][Full Text] [Related]
2. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
3. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
4. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
Chapman MJ; Guérin M; Bruckert E
Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
[TBL] [Abstract][Full Text] [Related]
5. [Free fatty acids: mediators of insulin resistance and atherosclerosis].
Castro Cabezas M; Erkelens DW; van Dijk H
Ned Tijdschr Geneeskd; 2002 Jan; 146(3):103-9. PubMed ID: 11826668
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus and macrovascular disease: mechanisms and mediators.
Boyle PJ
Am J Med; 2007 Sep; 120(9 Suppl 2):S12-7. PubMed ID: 17826041
[TBL] [Abstract][Full Text] [Related]
7. New aspects in the pathogenesis of diabetic atherothrombosis.
Moreno PR; Fuster V
J Am Coll Cardiol; 2004 Dec; 44(12):2293-300. PubMed ID: 15607389
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
Lebovitz HE
Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
[TBL] [Abstract][Full Text] [Related]
10. Diabetic dyslipidaemia: insights for optimizing patient management.
Vergès B
Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates.
Schäfer SA; Hansen BC; Völkl A; Fahimi HD; Pill J
Biochem Pharmacol; 2004 Jul; 68(2):239-51. PubMed ID: 15193996
[TBL] [Abstract][Full Text] [Related]
12. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
13. Hemostasis alterations in metabolic syndrome (review).
Palomo I; Alarcón M; Moore-Carrasco R; Argilés JM
Int J Mol Med; 2006 Nov; 18(5):969-74. PubMed ID: 17016629
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
15. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
17. [New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].
Fruchart JC; Staels B; Duriez P
Bull Acad Natl Med; 2001; 185(1):63-74; discussion 74-5. PubMed ID: 11474570
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Carmena R
Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
[TBL] [Abstract][Full Text] [Related]
19. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
20. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
